Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | GNAI3 | P08754 | 3/20 | 0.32 |
| ▸ | GNAO1 | P09471 | 3/20 | 0.32 |
| ▸ | GNAI1 | P63096 | 3/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.31 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23594109 | 0.85 | ALDH1A1 (0.36) | ALDH1A1NPC1GNAI3GNAO1GNAI1 | |
| SCHEMBL20034767 | 0.85 | ALDH1A1 (0.37) | SMN1; SMN2ALDH1A1NPC1LMNAGNAI3 | |
| SCHEMBL19698416 | 0.85 | ALDH1A1 (0.37) | SMN1; SMN2ALDH1A1NPC1LMNAGNAI3 | |
| SCHEMBL19703993 | 0.84 | NPC1 (0.47) | SMN1; SMN2ALDH1A1NPC1LMNAGNAI3 | |
| SCHEMBL24671788 | 0.82 | NPC1 (0.36) | ALDH1A1NPC1GNAI3GNAO1GNAI1 | |
| SCHEMBL25030012 | 0.81 | NPC1 (0.39) | ALDH1A1NPC1GNAI3GNAO1GNAI1 | |
| SCHEMBL26221592 | 0.81 | NPC1 (0.39) | ALDH1A1NPC1LMNAGNAI3GNAO1 | |
| SCHEMBL19703898 | 0.81 | ALDH1A1 (0.42) | SMN1; SMN2ALDH1A1NPC1LMNAGPR119 | |
| SCHEMBL23484948 | 0.81 | NPC1 (0.36) | ALDH1A1NPC1LMNAGNAI3GNAO1 | |
| SCHEMBL23484939 | 0.80 | GNAI3 (0.38) | ALDH1A1NPC1LMNAGNAI3GNAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355731-A1 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355731-A1 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | RNGTT, RNASE1, RNMT | SMN1; SMN2 2500/4885ALDH1A1 3212/4885NPC1 2704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.